National Bank of Canada FI Raises Position in MEI Pharma, Inc. (NASDAQ:MEIP)

National Bank of Canada FI lifted its holdings in shares of MEI Pharma, Inc. (NASDAQ:MEIP) by 43.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. National Bank of Canada FI owned about 0.50% of MEI Pharma worth $94,000 as of its most recent SEC filing.

Separately, Cable Car Capital LLC acquired a new position in MEI Pharma during the fourth quarter worth approximately $3,546,000. 52.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MEIP shares. Laidlaw downgraded MEI Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. StockNews.com assumed coverage on MEI Pharma in a research note on Thursday. They set a “buy” rating for the company. Finally, Brookline Capital Management lowered MEI Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 22nd. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, MEI Pharma has a consensus rating of “Hold” and an average target price of $7.00.

MEI Pharma Trading Down 1.0 %

MEIP stock opened at $3.03 on Friday. The company has a market capitalization of $20.18 million, a P/E ratio of 0.77 and a beta of 0.86. The firm has a 50 day simple moving average of $3.18 and a 200-day simple moving average of $3.27. MEI Pharma, Inc. has a twelve month low of $2.73 and a twelve month high of $7.87.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.